Platinum Sponsor

Life_280Thermo Fisher Scientific is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. www.thermofisher.com

Gold Sponsors

Cardio3_180Cardio3 BioSciences is a leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The Company’s lead product candidate, C-Cure®, is a highly innovative stem cell approach for the treatment of heart failure, one of the world’s most pressing unmet medical needs. Generated through a proprietary technological platform, the C3BS-CQR-1 programme is designed to direct the patient’s own stem cells into new heart cells with the potential to rebuild the heart. Cardio3 BioSciences has also developed C-Cath®ez, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium. Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium. The Company leverages research collaborations in the U.S. and in Europe with Mayo Clinic. www.c3bs.com

CTCatapult_160_websiteThe Cell Therapy Catapult is a centre of excellence for regenerative medicine. Its vision is for the U.K. to be a global leader in the development, delivery and commercialisation of cell therapy, and a place where businesses can start, and confidently grow. Based in London at Guy’s Hospital, the centre plans to take products into early clinical trials, providing clinical, technical, manufacturing and regulatory expertise and access to the NHS. This exciting initiative is the U.K.’s response to the translational gap between early-stage research and the later stages of clinical development in regenerative medicine. It is a dynamic new approach to developing products for unmet medical needs. Working with industry, academia, the NHS and government, the Cell Therapy Catapult will be shaping the U.K. regenerative medicine landscape. www.ct.catapult.org.uk

Fluidigm_220Fluidigm develops, manufactures and markets life science systems based on integrated fluidic circuits (IFCs). This technology furthers research by minimizing costs and enhancing sensitivity for applications such as single-cell gene expression, high-throughput SNP genotyping and next-generation sequencing. Single-cell genomic profiling has recently emerged as a powerful method to uncover heterogeneity in cell populations. In response to this, Fluidigm has developed a streamlined and automated workflow for capturing and analyzing single cells. The C1™ Single-Cell System isolates single cells starting with low cell number input. www.fluidigm.com

MiMedx_180MiMedx® is the premier processor of regenerative biomaterial products and implants from human amniotic membrane. MiMedx has distributed hundreds of thousands of amniotic tissue grafts worldwide. Profound clinical outcomes have been achieved in therapeutic areas including ophthalmology, spine, wounds, dental, orthopedic, surgery, sports medicine and urology. With this innovative allograft that promotes bioactive healing, MiMedx® believes its intellectual property and proprietary processing technique strategically positions the Company as the leader in this area of regenerative medicine. www.mimedx.com

PCT_200_Cropped_WebsiteProgenitor Cell Therapy (PCT) is an internationally recognized client-oriented service company, with a long-term commitment to the development, manufacturing and commercialization of cell therapies. PCT offers cost-effective turnkey service solutions for consulting and regulatory support, GLP/GTP/cGMP-compliant product development and manufacturing services, storage, distribution and logistics support, with the goal of establishing tailor-made service platforms providing the core benefits of operational leverage and control, financial value and risk mitigation. www.pctcelltherapy.com

Sangamo_120Sangamo BioSciences is a clinical-stage gene therapy company focused on Engineering Genetic Cures™ for monogenic and infectious diseases.  Sangamo is dedicated to the development of novel ZFP Therapeutics® using its proprietary zinc finger DNA-binding protein (ZFP) technology platform.  The Company has an ongoing Phase II clinical trial to evaluate the safety and efficacy of a novel T-cell based ZFP Therapeutic® for the treatment of HIV/AIDS. This application is being expanded into hematopoietic stem cells to enable the genetic engineering of an HIV-resistant immune system. The Company intends to file an IND application for this program in 2014. Sangamo’s other therapeutic programs are focused on stem cell applications in monogenic diseases such as hemoglobinopathies, including sickle cell disease and beta-thalassemia, and additional monogenic indications including hemophilia A and B, lysosomal storage disorders and Huntington’s disease. www.sangamo.com

SDI_225_websiteScottish Development International (SDI) is Scotland’s agency for economic development. Scotland’s stem cell and regenerative medicine cluster delivers a ”one-stop” solution for companies developing applications at preclinical, clinical or commercial stages of development. This dynamic commercial and academic landscape provides unique solutions across the whole supply chain including cell line supplies, screening, characterization, GMP manufacturing, QA/QC and a range of enabling technologies and other supporting services. Scotland has a proven track record in implementing cell therapy clinical trials using the world-class MHRA-accredited GMP ATMP manufacturing facilities for Phase I and II embryonic and adult stem cells. All of this expertise is in close proximity across Scotland with excellent connections to the rest of Europe. This makes Scotland the ideal location for academic research collaborations, stem cell technology research and development, clinical/translational research and cell line manufacturing. www.sdi.co.uk

Silver Sponsors

BioLife_195_updatedBioLife Solutions develops, manufactures and markets biopreservation media and high performance thermal packaging products for cells, tissues and organs. The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery and regenerative medicine markets. BioLife’s products are serum-free and protein-free, fully defined and are formulated to reduce preservation-induced cell damage and death.  BioLife’s enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues and organs. www.biolifesolutions.com

bluebird_155bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, is in a recently-initiated Phase II/III study, the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in two Phase I/II studies, one in the U.S. (the Northstar Study) and one in France (HGB-205), for the treatment of beta-thalassemia major. The Phase I/II HGB-205 study also allows enrollment of patients with sickle cell disease, and bluebird bio is planning a separate U.S. sickle cell disease trial (HGB-206). www.bluebirdbio.com

CCRM_140The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian not-for-profit, public-private consortium funded by the Government of Canada’s Networks of Centres of Excellence program, six Ontario-based institutional partners and more than 30 companies representing the key sectors of the regenerative medicine industry. CCRM supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. The office, located at the Banting Institute at the University of Toronto, has a 6,000 square foot development facility that houses three platforms: Cell Reprogramming and Engineering; Cell Manufacturing; and, Biomaterials and Devices. A network of academics, industry and entrepreneurs, CCRM translates scientific discoveries into marketable products for patients. CCRM launched in Toronto’s Discovery District on June 14, 2011. www.ccrm.ca

Cellular-Dynamics_135Cellular Dynamics International is a leading developer of fully functional human cells derived from induced pluripotent stem (iPS) cells. The Company’s iCell® and MyCell® product lines provide industrial quantities of high quality, highly pure human cells enabling disease modeling, drug discovery, toxicity testing and regenerative medicine research. www.cellulardynamics.com

Fresenius-Kabi_140Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Everything we do at Fresenius Kabi has one ultimate purpose: to put lifesaving medicines and technologies in the hands of people who care for patients, and to find answers to the challenges they face. Fresenius Kabi is pleased to now offer the Fenwal portfolio of transfusion technologies including the Amicus therapeutic apheresis and cell collection platform for therapeutic plasma exchange (TPE) and MNC collection. www.fresenius-kabi.us

GE-Healthcare_80GE Healthcare Life Sciences provides tools for drug discovery, biopharmaceutical manufacturing and cellular technologies, so research scientists and specialists around the world can be more productive, effective and creative. Our vision is to be the start-to-finish bioprocessing solution provider, the partner of choice in cell and protein research, and the leader in life sciences services. Building on our broad expertise across life sciences, we are firmly committed to help researchers understand life at a molecular level and develop solutions that can prevent, diagnose, treat and cure disease. With our “healthymagination” initiative, we invite the world to join us on our journey as we continue to drive innovation focused on reducing costs, increasing access and improving quality and efficiency in healthcare around the world. GE Healthcare Life Sciences employs more than 5,000 people in more than 100 countries. www.gelifesciences.com

JanssenR&D_140At Janssen Research & Development we are united and energized by one mission—to discover and develop innovative medicines that ease patients’ suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies of Johnson & Johnson, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in oncology, immunology, neuroscience, infectious diseases and vaccines and cardiovascular and metabolic diseases. www.janssenrnd.com

Lonza_150Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. www.lonza.com

Medpace_170Medpace is a global full-service Clinical Research Organization (CRO) providing comprehensive development services for drug, biologic and device programs. Medpace has strong experience supporting development programs for regenerative medicine products across a number of therapeutic areas including cardiovascular, neuroscience, musculoskeletal and diabetes. With extensive medical expertise, a renowned regulatory affairs department and direct global operations in over 40 countries, Medpace conducts studies and navigates regulatory requirements worldwide. From feasibility, research site compatibility, safety and logistics, Medpace brings efficiencies and operational excellence to regenerative medicine development programs. In addition, Medpace offers integrated imaging and lab capabilities through its family of companies to provide cohesive, streamlined and standardized trial management. www.medpace.com

Mesoblast_185Mesoblast Limited is developing novel biotherapeutics derived from its proprietary adult stem cell-based technologies. The Company’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs. Its strategic product development focus is in four major and distinct areas – systemic inflammatory conditions, cardiovascular diseases, orthopedic diseases of the spine and oncology conditions. Mesoblast’s corporate strategy is to leverage proprietary cell-based and complementary biologic technologies to develop products for unmet medical needs; bring multiple products to market within a parallel timeframe; underpin future financial growth through investing in manufacturing operations; and enhance the likelihood of commercial success through strategic partnerships. Mesoblast’s strong cash reserves ($315M) enable simultaneous product development with future revenues expected from milestone payments, distribution arrangements and direct sales. www.mesoblast.com

Organovo_175Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. www.organovo.com

Terumo-BTC-LogoTerumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. www.terumobct.com

Bronze Sponsors

Alexandria_150Alexandria Real Estate Equities is the largest and leading REIT uniquely focused on collaborative science and technology campuses in urban innovation clusters including San Diego, Greater Boston, the San Francisco Bay Area, New York City, Seattle, Research Triangle Park and Maryland. Alexandria has a longstanding and proven track record of developing Class A assets clustered in urban science and technology campuses that provide its client tenants with highly collaborative, 24/7, live/work/play ecosystems, as well as the critical ability to successfully recruit and retain best-in-class talent and enhance productivity. www.are.com

Allele_100Allele Biotechnology & Pharmaceuticals develops proprietary methods and tools for non-integrating cellular reprogramming, enabling drug discovery models and cell therapy including human and non-human primate iPS cells, GMP production of human iPS cells and their derivatives and the generation of differentiated cell types. With our expertise in genome modification, next generation sequencing technology and fluorescent reporters, Allele provides complete cell generation and assay development solutions. Allele Biotechnology and Pharmaceuticals is a privately owned San Diego-based biotechnology company with the goal of advancing discovery and innovation. Founded in 1999 by scientists and other professionals, Allele explores the mechanisms of biological processes to develop technologies and products for biomedical researchers in industry and academia. In addition to cellular reprogramming, Allele specializes in nano-antibody development and reagents, fluorescent protein development and mRNA based genome modification. www.allelebiotech.com

Capricor_140Los Angeles-based Capricor Therapeutics is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and large molecule products for the treatment of diseases. Capricor’s lead product candidate, an allogeneic cardiosphere-derived cell (CDC) product, CAP-1002, aims to attenuate and potentially improve damage to the heart caused by a heart attack, and is currently under evaluation in the Phase I/II ALLSTAR clinical trial of patients 30-days to 1-year after a heart attack. Additionally, Capricor plans to explore development of exosome technology as a next generation regenerative medicine platform in a variety of cardiovascular and non-cardiovascular areas. Groundbreaking preclinical research has demonstrated that exosomes extracted from Capricor’s CDCs reduced scar tissue caused by a heart attack and prompted myocardial regeneration in preclinical models of ischemic heart disease. www.capricor.com

Celgene_65Since its beginnings, Celgene has experienced tremendous growth and geographic expansion. The Celgene of today is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives, reducing the burden on healthcare systems and helping economies grow. Today, Celgene employs world-class biopharmaceutical talent across the globe, and for all of its growth and expansion, Celgene remains true to its DNA – a genetic heritage based on a promise that runs from generation to generation. A promise to support, nurture and create medical innovation, to think differently, to disrupt, to be bold, to be agile and to persevere. It is a promise to change the course of human health while always putting patients first. www.celgene.com

CellGenix_140CellGenix manufactures GMP reagents for ex-vivo cell culture of DC’s, T-Cells, NK-Cells, HSC’s and MSC’s. We follow strict guidelines to ensure reliability, safety and reproducible results for preclinical and clinical applications. CellGenix products are used in clinical centers worldwide in cancer and regenerative medicine. www.cellgenix.com

CTI_140_websiteCTI Clinical Trial & Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization, with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in solid organ and stem cell transplantation, immunology, infectious disease, hematology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, Ohio, CTI has offices in North America, Europe and South America. www.ctifacts.com

Cytomedix_135Cytomedix is an autologous regenerative therapies company commercializing innovative platelet technologies for wound care. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma (PRP) gel for use on a variety of exuding wounds. www.cytomedix.com

EBD_60EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify and develop strategic relationships. 
Our conferences, run with the support of leading corporations and international trade associations, include BIO-Europe®, BIO-Europe Spring®, BioPharm America™, EuroMedtech™, BioEquity Europe, ChinaBio® Partnering Forum, The Global Impact Forum™ and Biotech Showcase™.
 EBD Group’s sophisticated web-based partnering service, partneringONE®, also powers numerous third-party events, and partnering360® is the online community of life science executives that enhances dealmaking productivity year round. www.ebdgroup.com

EMD-Millipore_60EMD Millipore, a division of Merck KGaA, Darmstadt, Germany, offers solutions that enable scientists to conduct life science research easily, efficiently and economically. With a range of stem cell products, services and dedicated experts, EMD Millipore serves as a strategic partner to customers and helps advance stem cell science. We are deeply committed to providing novel cell culture systems and characterization tools to meet your needs from stem cell research to cGMP manufacturing. Our highly validated, optimized products provide convenient solutions to many cell culture challenges, so you have the time to focus on your research and clinical goals. www.emdmillipore.com

Histogenics_140Histogenics was incorporated in 2000 with an initial focus of developing products that meaningfully improve the lives of patients with defects in cartilage and joints. In May 2011, the Company acquired ProChon Biotech, a privately-owned biotechnology company based in Israel, which enabled a synthesis of products, technology and materials science by establishing a robust scientific and technology platform targeting tissue repair solutions. Histogenics’ goal is to become a leading regenerative medicine company developing, marketing and commercializing products in the musculoskeletal segment of the marketplace. The Company is building its core technology platform and plans to expand its clinical products’ therapeutic applications to develop new and innovative solutions for musculoskeletal conditions. Histogenics leverages a combination of the latest advances in molecular biology and proprietary materials sciences to create products designed to help improve patient outcomes. www.histogenics.com

LMRI_145The Lowy Medical Research Institute (LMRI) was established in 2004, with the goal of carrying out innovative research into human diseases. LMRI is currently focused on the study of a neuro-/vasculodegenerative disease of the retina, idiopathic juxtafoveal macular telangiectasia type 2, or MacTel. In addition to the Institute with a full time staff in La Jolla, California, the LMRI supports multinational natural history and interventional clinical trials as well as international laboratory collaborations in North America, Europe, Asia and Australia. www.lmri.net

Osiris_100Through over 20 years of research, experience and understanding, Osiris Therapeutics has led the way in mesenchymal stem cell (MSC) science and the clinical application of cellular therapies. From commercializing its first generation implantable product, Osteocel, to achieving the Company’s initial goal, when founded in 1992, of developing the world’s first approved stem cell drug, remestemcel-L for graft versus host disease, Osiris has written the book on regenerative medicine. Today, as the leading stem cell company, Osiris continues to address unmet medical needs with innovative approaches in developing and marketing products in wound care, orthopedics and sports medicine. Never forgetting that our products are differentiated by scientific excellence, Osiris’ current product line includes Grafix® for acute and chronic wounds, Cartiform®, a viable cartilage mesh for cartilage repair, and OvationOS®, a viable bone matrix used for bone repair and regeneration. www.osiris.com 

Pall_150Pall Life Sciences provides process, pilot and laboratory filtration, separation, purification and fluid handling devices, systems and services, with single-use systems available for all unit operations from cell culture – including cell therapy applications – through final formulation and filling. Based on Pall’s long history of providing quality equipment for the biopharmaceutical, vaccine and cell therapy industries, all products – whether standard or customized to match users’ exact process needs – are backed up with extensive documentation and experience in extractables, leachables and particulate validation. Fully automated single-use systems allow process control and data acquisition to meet or exceed the standards expected from traditional fixed equipment. New product highlights include microcarriers, pyrogen-free vials and a range of pharmaceutical packaging. www.pall.com/biopharm 

Sartorius_140Sartorius Stedim Biotech is a world leader in laboratory and production scale bioprocessing technologies, focused strongly on innovation in process analytic technologies (PAT). The single-use stirred bioreactor line, BIOSTAT® STR, scales from 2 to 2,000 liters and is complemented by industry standard pH and DO monitoring as well as cutting edge on-line glucose and cell capacitance through BIOPAT® Trace and ViaMass respectively. Investments in the Flexsafe film material for its single-use systems including the rocking motion technologies, BIOSTAT® RM, offer reproducible cell growth, superior robustness and assurance of supply. The recent acquisition of TAP Biosystems expands our expertise to include automated parallel processing and dynamic scheduling, through disruptive offerings such as ambr15™ and 250™, further transforming process optimization and development for the future. Sartorius operates production facilities in Europe, Asia and America with sales offices and local representatives in more than 110 countries, all dedicated to “turning science into solutions” each day. www.sartorius.com

S&N_150Smith & Nephew Biotherapeutics, a bioactive specialized area within Smith & Nephew, is focused on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration. Its research and development strategy is centered on next-generation bioactive therapies for the treatment of chronic wounds and burns. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and REGRANEX® (becaplermin) Gel 0.01%. Smith & Nephew Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®. Smith & Nephew Biotherapeutics is based in Fort Worth, Texas. www.smith-nephew.com

StemBioSys_150StemBioSys, based in San Antonio, Texas, is a privately-held biomedical company focused on the isolation, growth and delivery of adult stem cells for clinical use. Its patented and proprietary technology platforms – licensed from the University of Texas Board of Regents – overcome key obstacles to creating clinically useful stem cell therapies. The centerpiece of these enabling technologies is the HPMETM (High Performance Micro Environment™) platform. This cell derived three-dimensional microenvironment allows a variety of stem cells to replicate more rapidly and with greater preservation of stem cell properties compared to more traditional tissue culture substrates. This disruptive technology is positioned to transform and improve the methods and cost of isolating, growing and delivering various stem cell populations for applications in research, therapeutic applications and drug discovery. We are currently ramping up GMP production of the core HPME product in preparation for proof of concept testing in various applications. www.stembiosys.com

STEM_150StemCells, Inc. is engaged in the research and clinical development of cell-based therapeutics using the Company’s platform technology, consisting of a proprietary highly purified population of human neural stem cells, HuCNS-SC® cells. The Company is developing therapies for the treatment of a broad range of central nervous system disorders. StemCells, Inc. has completed enrollment in a Phase I/II clinical trial in spinal cord injury in Switzerland and Canada, and has reported positive data for the first eight patients. Final results will be available next year. The Company is conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) which is expected to complete enrollment and report final results next year. The Company is also pursuing preclinical studies in Alzheimer’s disease with funding support from the California Institute of Regenerative Medicine. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of donor-derived myelination in all four patients transplanted with HuCNS-SC cells. StemCells, Inc. also markets stem cell research products, including media and reagents, under the SC Proven® brand. www.stemcellsinc.com


TiGenix, founded in the year 2000 to clinically develop and bring to market novel cell therapeutic products, is the only European cell therapy company that benefits from the combination of top-line sales (through its marketed product ChondroCelect) and long term growth potential through its pipeline of adipose-derived stem cell products. TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the EMA. Its lead candidate is Cx601, currently finalizing the recruitment of a single pivotal Phase III in Europe for complex perianal fistulas in Crohn’s patients. The results are expected Q3 2015 and filing for approval in Europe in the first half of 2016. After a successful end of Phase II meeting with the FDA, the Company will file for an SPA before the end of 2014 for the second pivotal trial that will allow for a BLA filing. TiGenix announced recently the clinical development of Cx611, its intravenous-administered allogeneic stem cell product, in early rheumatoid arthritis and severe sepsis. www.tigenix.com

WuXi_120WuXi AppTec supports the contract development and cGMP manufacture of allogeneic and autologous cell-based therapeutics. Our fully-integrated service platforms span from process development to biological safety testing and release. A combination of state-of-the-art facilities, expertise and service options provide clients a distinct advantage – a unique, single-source solution. Services include: GMP/GTP manufacturing/aseptic processing, process development, GMP cell banking and cell line characterization, analytical (e.g., flow cytometry) and adventitious agent testing (e.g., sterility, bioburden, mycoplasma and virus detection) for lot release and stability, biodistribution, toxicology, biocompatibility, package integrity testing, shipping and cleaning validations and environmental monitoring. www.wuxiapptec.com


Life-Science-Report_170The Life Sciences Report has a unique formula for reaching investors, both institutional and retail, via our in-depth expert-interviews, which help educate the investor community and propel growth in the regenerative medicine, biotechnology, pharmaceutical and medical devices sectors. Our combination of information and insight coupled with our broad distribution is a unique feature not found anywhere else. www.thelifesciencesreport.com

ProActive_140ProActive Capital Group (PCG) is dedicated to the discovery and creation of value specifically in the emerging public company marketplace. The Company provides unique solutions that combine capital markets advisory and strategic communications. PCG’s overarching goal is to develop and leverage stakeholder awareness from all key constituents in order to maximize shareholder value. PCG’s capital markets advisory services include overall investor strategy development to increase and leverage awareness, visibility and credibility. The Company’s strategic communications services leverage traditional, digital and social media channels to further increase awareness to all key constituents. www.proactivecapital.com

SCTM_170Stem Cells Translational Medicine (SCTM) features high-impact, peer-reviewed articles based in stem cell research that are translational in nature, i.e., moving from preclinical to clinical trials and ultimately to curing disease with stem cell-based therapies and regenerative medicine. From its inception in 2012, SCTM covers topics ranging from stem cell biology and tissue engineering to regenerative medicine, publishing content showing the resourceful translation and commercialization of stem cells research to gain acceptance with importance indices such as MEDLINE/PubMed before the completion of its first year and then receiving an inaugural Impact Factor of 3.596 in 2014. www.stemcellstm.alphamedpress.org


    “Life Technologies has sponsored this meeting since its inception in 2006, and helped it grow into a leading, annual conference for the regenerative medicine community. Whether your goal is to gain exposure to researchers or put your name out in front of C-level executives, sponsoring this meeting has incredible value.”

    -- Alaine Maxwell, Senior District Manager, Western Canada, Life Sciences Solutions, Life Technologies, A Thermo Fisher Scientific Brand